Status:
COMPLETED
Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis
Lead Sponsor:
Dong-A University
Conditions:
Actinic Cheilitis
Eligibility:
All Genders
18-92 years
Phase:
PHASE1
Brief Summary
Methyl aminolaevulinate photodynamic therapy (MAL-PDT) is advantageous in that it has few cosmetic side effects and minimises patient discomfort. However, its relatively low efficacy prevents its appl...
Detailed Description
Actinic cheilitis (AC) is a keratinocytic neoplasm of the lip, especially the lower lip, is confined to the epidermis, and results from chronic or excessive ultraviolet exposure. AC is an early manife...
Eligibility Criteria
Inclusion
- Korean patients ≥ 18 years of age who had biopsy-confirmed AC lesions
Exclusion
- porphyria
- known allergies to the MAL cream or lidocaine
- pregnancy
- lactation
- any active systemic infectious disease
- immunosuppressive treatment
- personal history of malignant melanoma
- tendency towards melasma or keloid formation
- prior treatment of the lesions within 4 weeks
- any indication of poor compliance
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT02198469
Start Date
January 1 2012
End Date
March 1 2014
Last Update
July 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dong-A University
Busan, Dong Dae Sin-dong, Seo-gu, South Korea, 602-715